Premium
Antitumor activity of ilmofosine (BM 41.440) in the 3 Lewis‐lung carcinoma model
Author(s) -
Herrmann Dieter B. J.,
Opitz HansGeorge,
Munder Paul G.
Publication year - 1991
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/bf02536581
Subject(s) - lewis lung carcinoma , in vivo , cyclophosphamide , cytotoxic t cell , clinical chemistry , carcinoma , chemistry , lipidology , lung , cancer research , medicine , in vitro , pathology , chemotherapy , biology , cancer , biochemistry , metastasis , microbiology and biotechnology
Ilmofosine (1‐hexadecylthio‐2‐methoxymethyl‐1,3‐propanediol‐phosphocholine, BM 41.440) is a thioether phospholipid with cytostatic/cytotoxic properties. The antineoplastic activity of this compound was investigated in vivo in the 3 Lewis‐lung carcinoma system. 3 Lewis lung tumor‐bearing C57Bl/6 mice were treated with 0.625 to 40 mg Il‐mofosine/kg per day p.o. either from days 1 to 9 or from days 11 to 28 after intrafoot‐pad tumor cell inoculation. Ilmofosine caused a significant dose‐related response on tumor growth and metastases, expressed in terms of tumor diameter, tumor weight, survival time and number of metastases‐free animals as compared to sham‐treated and positive (cyclophosphamide) controls. The results suggest that direct cytostatic/cytotoxic effects, rather than immune‐modulatory mechanisms, preferentially contribute to the antitumor activity of Ilmofosine in vivo .